After finishing at $2.79 in the prior trading day, Esperion Therapeutics Inc. (NASDAQ: ESPR) closed at $2.88, up 3.23%. In other words, the price has increased by $+0.0900 from its previous closing price. On the day, 6288689 shares were traded.
Ratios:
Our goal is to gain a better understanding of ESPR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.29.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 20 ’23 when Warren Eric sold 742 shares for $1.25 per share. The transaction valued at 924 led to the insider holds 68,318 shares of the business.
Warren Eric sold 243 shares of ESPR for $344 on Aug 18 ’23. The Chief Commercial Officer now owns 69,060 shares after completing the transaction at $1.41 per share. On Jul 19 ’23, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 106 shares for $1.58 each. As a result, the insider received 168 and left with 69,303 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 531.10M and an Enterprise Value of 715.02M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22. Its current Enterprise Value per Revenue stands at 6.15 whereas that against EBITDA is -4.76.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $3.34, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 2.3982, while the 200-Day Moving Average is calculated to be 1.7107.
Shares Statistics:
The stock has traded on average 6.44M shares per day over the past 3-months and 9.63M shares per day over the last 10 days, according to various share statistics. A total of 170.42M shares are outstanding, with a floating share count of 168.54M. Insiders hold about 1.10% of the company’s shares, while institutions hold 48.10% stake in the company. Shares short for ESPR as of Mar 15, 2024 were 17.67M with a Short Ratio of 2.74, compared to 18.57M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.55% and a Short% of Float of 10.66%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.46 and a low estimate of -$0.31, while EPS last year was -$0.79. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.14 and low estimates of -$0.25.
Analysts are recommending an EPS of between $0.09 and -$1 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is $0.05, with 6 analysts recommending between $1.49 and -$0.67.
Revenue Estimates
8 analysts predict $84.51M in revenue for the current quarter. It ranges from a high estimate of $144.57M to a low estimate of $28.9M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $24.33M, an estimated increase of 247.40% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $42.53M, an increase of 64.90% less than the figure of $247.40% in the same quarter last year. There is a high estimate of $50.66M for the next quarter, whereas the lowest estimate is $38M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $328.2M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $265.13M. In the same quarter a year ago, actual revenue was $116.33M, up 127.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $391.03M in the next fiscal year. The high estimate is $710.2M and the low estimate is $266.1M. The average revenue growth estimate for next year is up 47.50% from the average revenue estimate for this year.
